Most Read Articles
19 Jun 2019
Acquired immunodeficiency syndrome (AIDS) remains as one of the world’s leading causes of mortality in global public health. Dr Charles Hicks shared his insights into the increasing role of dolutegravir (DTG; Tivicay, GSK) – an integrase strand transfer inhibitor (INSTI) – in HIV therapy during the 4th National AIDS Conference 2018 at Swiss Garden International Hotel and Residences, Kuala Lumpur.
19 Jun 2019
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 3 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.

Stage 1 hypertension strongly predicts 10-year CVD events

19 May 2019

Stage 1 hypertension but not elevated blood pressure (BP) appears to be associated with a significant increase in the incidence of fatal and nonfatal cardiovascular disease (CVD) events over a 10-year follow-up, according to data from the ATTICA study.

The analysis involved 3,042 randomly selected Greek adults aged 18–89 years. Hypertension status was defined based on mean systolic/diastolic blood pressure and the most recent 2017 ACC/AHA guidelines: high normal blood pressure (HNBP; systolic, 120–139 mm Hg; diastolic, 80–89 mm Hg; no prior history of high blood pressure), elevated BP (systolic, 120–129 mm Hg; diastolic, <80 mm Hg) and stage 1 hypertension (systolic, 130–139 mm Hg; diastolic, 80–89 mm Hg).

In the cohort, the prevalence rates of HNBP, elevated BP and stage 1 hypertension were 44.6 percent (n=626), 29.0 percent (n=408) and 15.5 percent (n=218), respectively.

Incident fatal and nonfatal CVD events during follow-up of 10 years occurred in 98 patients (15.6 percent) in the HNBP group, 49 (12.0 percent) in the elevated BP group and 49 (22.5 percent) in the stage 1 hypertension group as compared with 49 (6.3 percent) in the normotension group (p<0.0001 for all).

Relative to normal BP, HNBP and stage 1 hypertension contributed to an increased risk of 10-year CVD. The risk increased by 1.5-fold with HNBP (adjusted hazard ratio [aHR], 1.49; 95 percent CI, 1.00–2.20) and by twofold with stage 1 hypertension (aHR, 1.90; 1.16–3.08). The risk increase was particularly pronounced in males (aHR, 2.03; 1.08–3.83).

On the other hand, elevated BP was not associated with an increased risk of developing 10-year CVD events (aHR, 1.28; 0.82–2.02).

In light of a notable increased risk of 10-year fatal and nonfatal CVD events associated with HNBP and stage 1 hypertension, researchers called for the implementation of targeted primary and secondary prevention interventions that may deter both CVD and related adverse health outcomes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Jun 2019
Acquired immunodeficiency syndrome (AIDS) remains as one of the world’s leading causes of mortality in global public health. Dr Charles Hicks shared his insights into the increasing role of dolutegravir (DTG; Tivicay, GSK) – an integrase strand transfer inhibitor (INSTI) – in HIV therapy during the 4th National AIDS Conference 2018 at Swiss Garden International Hotel and Residences, Kuala Lumpur.
19 Jun 2019
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 3 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.